These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 24287070)

  • 1. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?
    Hutchings M
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):87-103. PubMed ID: 24287070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
    Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
    Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
    Qiu L; Chen Y; Wu J
    Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDG-PET imaging for Hodgkin lymphoma: current use and future applications.
    Kostakoglu L; Evens AM
    Clin Adv Hematol Oncol; 2014 Jan; 12(1):20-35. PubMed ID: 25000313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET in the clinical management of Hodgkin lymphoma.
    Hutchings M; Eigtved AI; Specht L
    Crit Rev Oncol Hematol; 2004 Oct; 52(1):19-32. PubMed ID: 15363464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET/CT for therapy response assessment in lymphoma.
    Hutchings M; Barrington SF
    J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma?
    Hutchings M
    Hematology Am Soc Hematol Educ Program; 2012; 2012():322-7. PubMed ID: 23233599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.
    Evens AM; Kostakoglu L
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):135-43. PubMed ID: 25696846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma.
    Hutchings M; Loft A; Hansen M; Pedersen LM; Berthelsen AK; Keiding S; D'Amore F; Boesen AM; Roemer L; Specht L
    Haematologica; 2006 Apr; 91(4):482-9. PubMed ID: 16585015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
    De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
    J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of PET in lymphoma.
    Jhanwar YS; Straus DJ
    J Nucl Med; 2006 Aug; 47(8):1326-34. PubMed ID: 16883013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Haematologica; 2001 Mar; 86(3):266-73. PubMed ID: 11255273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early interim PET scan in Hodgkin lymphoma: where do we stand?
    Gallamini A; Hutchings M; Avigdor A; Polliack A
    Leuk Lymphoma; 2008 Apr; 49(4):659-62. PubMed ID: 18398732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interim 18F-FDG PET in Hodgkin lymphoma: would PET-adapted clinical trials lead to a paradigm shift?
    Kostakoglu L; Gallamini A
    J Nucl Med; 2013 Jul; 54(7):1082-93. PubMed ID: 23818548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
    Schaefer NG; Veit-Haibach P; Soyka JD; Steinert HC; Stahel RA
    Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of FDG-PET/CT in the management of lymphoma.
    Baba S; Abe K; Isoda T; Maruoka Y; Sasaki M; Honda H
    Ann Nucl Med; 2011 Dec; 25(10):701-16. PubMed ID: 22037934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk- and response-adapted strategies for the management of Hodgkin lymphoma.
    Remer M; Johnson PW
    Chin Clin Oncol; 2015 Mar; 4(1):13. PubMed ID: 25841720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies.
    El-Galaly TC; Hutchings M
    Cancer Treat Res; 2015; 165():125-46. PubMed ID: 25655608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A strange case of phyllodes tumor detected using (18)F-FDG PET/CT in an adolescent patient affected by Hodgkin lymphoma: a possible pitfall.
    Cucinotta M; Quartuccio N; Coppolino P; La Delfa V; Bianchi M; Fagioli F; Cistaro A
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):e201-5. PubMed ID: 25240649
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.